Moderna (MRNA) Expected to Announce Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) will likely be issuing its quarterly earnings data before the market opens on Friday, February 14th. Analysts expect the company to announce earnings of ($2.86) per share and revenue of $951.09 million for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Moderna Price Performance

Shares of NASDAQ MRNA opened at $30.53 on Thursday. Moderna has a fifty-two week low of $30.24 and a fifty-two week high of $170.47. The business has a 50 day moving average price of $39.53 and a two-hundred day moving average price of $56.11. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The firm has a market cap of $11.75 billion, a PE ratio of -5.25 and a beta of 1.59.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on MRNA shares. Berenberg Bank raised their price objective on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Friday, November 8th. Bank of America reduced their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday. Sanford C. Bernstein initiated coverage on Moderna in a report on Thursday, October 17th. They set a “market perform” rating and a $55.00 target price on the stock. Finally, The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $66.89.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of Moderna stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 2,664 shares of company stock valued at $115,210 over the last quarter. Insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.